SCOV 1
Alternative Names: COVID-19 DNA vaccine - Scancell; SCOV1; SN 15Latest Information Update: 28 Nov 2024
At a glance
- Originator Scancell
- Developer Nottingham Trent University; Scancell; University of Nottingham
- Class COVID-19 vaccines; DNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - COVID 2019 infections
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention) in South Africa (IM, Injection)
- 28 Nov 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention) in South Africa (Intradermal, Injection)
- 13 Feb 2023 Immunogenicity and adverse events data from a phase I COVIDITY trial for COVID-2019 infections released by Scancell